Delcath Systems, Inc.

NASDAQ:DCTH

Medical - Devices

Healthcare
$19.24 -1.91%

-$0.23 today

Market cap
$669.32M
Beta
0.52
P/E (TTM)
751.4
EPS (TTM)
$0.02
52W Low $8.12High $14.48

Volume 0.46M

Average 0.42M

Returns on capital

Delcath Systems, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

2.4%

avg -490.0%

ROIC

0.5%

avg -45.8%

ROA

2.2%

avg -136.6%

Analysis

ROE is currently the strongest return metric at 2.4% versus its period average of -490.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Gerard J. Michel

Chief Executive Officer & DirectorUSD 990.71K63342.03K0.99%

Vojislav Vukovic

Chief Medical OfficerUSD 672K59——

Martha S. Rook

Chief Operating OfficerUSD 640.83K5628.25K0.08%

Johnny John

Senior Vice President of Medical & PharmacovigilanceUSD 472.16K6259.81K0.17%

Kevin Muir

Chief Commercial OfficerUSD 394.4K—28.25K0.08%

Michael Brunner

Senior Vice President of Interventional Oncology————

David Hoffman

General Counsel, Corporate Secretary & Chief Compliance Officer—56——

Sandra Pennell

Chief Financial Officer—4777.02K0.22%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$189,319.30

Sells

2

$488,508.00

Net Transaction Value

−$299,188.70

Net selling

Most Active

Martell Bridget A

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 12, 26

Martell Bridget A

Direct

Sell$445.5K
Nov 12, 26

Martell Bridget A

Direct

Sell$43K
Mar 6, 26

Pennell Sandra

Direct

Buy$50K
Mar 2, 26

MICHEL GERARD J

Direct

Buy$100.3K
Nov 21, 25

Sylvester John Richard

Direct

Buy$39K

Summary

Insiders reported 3 buys worth $189,319.30 and 2 sells worth $488,508.00 over the last 12 months. That adds up to net selling of $299,188.70. Martell Bridget A was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+75.6% (5yr)1 analysts
RevenueN/AN/A+215.3%
+22.2% (5yr)2 analysts
Net IncomeN/AN/AN/A
+75.6% (5yr)2 analysts
EBITN/AN/AN/A
+144.4% (5yr)2 analysts

Analysis

Recent growth has been strongest in Revenue at +215.3% over three years. Forward estimates point to EBIT at +144.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Delcath Systems, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about DCTH's management, answered from reported figures.

Who manages DCTH?

Delcath Systems, Inc. (DCTH) lists 8 active executives. The top listed executive is Johnny John, Senior Vice President of Medical & Pharmacovigilance.

Are DCTH insiders buying or selling?

Recent insider activity shows net buying of $11.61B.